Hengrui Pharma Announces Strong 2025 Annual Results
HONG KONG, Mar 25, 2026 – (ACN Newswire via SeaPRwire.com) – On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13.02% year-on-year to RMB 31.63 billion, and net profit attributable to shareholders increased by 21.69% to […]